

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:





English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001077092	A1	20011018	WO 2001-KR585	20010407
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			KR 2000-18327	A 20000407
			KR 2000-18328	A 20000407
			KR 2000-18431	A 20000408

GI



AB The present invention provides novel sulfonamide derivs. (I (e.g. (2R)-3-methyl-2-[(2-phenylthiobenzothiazole-6-sulfonyl)amino]butanoic acid Me ester), II (n = 0-4) and III (n = 0-4)), useful as an inhibitors of matrix metalloproteinase (MMP), its isomers, **pharmaceutically** acceptable salts thereof and a process for prepg. the same. Since the sulfonamide derivs. of the present invention selectively inhibit MMP activity in vitro, the MMP inhibitors comprising the sulfonamide derivs. as an effective ingredient can be practically applied for the prevention and treatment of all sorts of diseases caused by overexpression and overactivation of MMP. In I: R1 denotes H, C1-12 alkyl, carbocyclic

aryl-lower alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl-lower alkyl, (oxo, amino or thio) C3-7 cycloalkyl, (oxo, amino or thio) C3-7 cycloalkyl-lower alkyl, C2-12 lower alkenyl, C2-12 lower alkynyl, carbocyclic aryl, heterocyclic aryl, heterocyclic aryl-lower alkyl, biaryl, halo lower alkyl, biaryl-lower alkylarylalkyl, hydroxy-lower alkyl, alkoxyalkyl, acyloxy-lower alkyl, alkyl or aryl (thio, sulfinyl or sulfonyl) lower alkyl, (amino, mono or dialkylamino) lower alkyl, acylamino lower alkyl, (N-lower alkylpiperazino, or N-carbocyclic or heterocyclic aryl-lower alkylpiperazino)-lower alkyl or (morpholino, thiomorpholino, piperidino, pyrrolidino or piperidyl)-lower alkyl. R2 denotes H, lower alkyl, carbocyclic aryl-lower alkyl, C1-4 carbocyclic aryl-lower alkyl, C1-4 heterocyclic aryl-lower alkyl, C1-5 alkoxyphenyl-lower alkyl, C1-5 alkenoxyphenyl-lower alkyl, C1-5 alkynoxyphenyl-lower alkyl, heterocyclic aryl-lower alkyl, hydroxy-lower alkyl, alkoxyalkyl, acyloxy-lower alkyl, thio-lower alkyl, alkyl or aryl (thio, sulfinyl or sulfonyl) lower alkyl, (amino, mono or dialkylamino) lower alkyl, carboxy-lower alkyl, (amino, mono or dialkylamino) lower alkyl or acylamino lower alkyl. R3 denotes H or C1-6-lower alkyl. R4 denotes H, C1-12 alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl-lower alkyl, (oxo, amino or thio) C3-7 cycloalkyl, (oxo, amino or thio) C3-7 cycloalkyl-lower alkyl, carbocyclic aryl, carbocyclic aryl-lower alkyl, heterocyclic aryl, heterocyclic aryl-lower alkyl, biaryl, biaryl-lower alkyl, halo lower alkyl, hydroxy-lower alkyl, alkoxyalkyl, acyloxy-lower alkyl, alkyl or aryl (thio, sulfinyl or sulfonyl) lower alkyl, (amino, mono or dialkylamino) lower alkyl, acylamino lower alkyl, carboxy lower alkyl, (N-lower alkylpiperazino, or N-carbocyclic or heterocyclic aryl piperazino)-lower alkyl or (morpholino, thiomorpholino, piperidino, pyrrolidino or piperidyl)-lower alkyl. R5 denotes hydroxy, alkoxy, halogen, thiol, thioalkoxy or hydroxylamine. X1 and X2 denote N-R7 (R7 is H, C1-6-lower alkyl, aryl, heteroaryl or arylalkyl), S or O. I can be prepd. by (i) reacting a sulfonyl halide with H2NCR2R3CO2R6 (R6 = protecting group) in an org. solvent in the presence of a base to give a sulfonamide; (ii) replacing the H on N using R4-L (L = reactive leaving group) in an org. solvent in the presence of a base; and (iii) hydrolyzing the intermediate to give I (R5 = OH), or further condensing I (R5 = OH) to prep. I (R5 = NHOH). Alternatively, I can be prepd. by (i) chlorosulfonylating IV; (ii) reacting this intermediate with an amino acid deriv. in an org. solvent in the presence of base to give a sulfonamide; (iii) heating this intermediate and R1-X2H together at 70 to 80.degree. in an org. solvent in the presence of base to cause substitution for Cl; (iv) reacting this intermediate with R4-L (L = reactive leaving group) in an org. solvent in the presence of base to cause substitution for H on N; and, (v) hydrolyzing this intermediate into I (R5 = OH), or further condensing I (R5 = OH) to prep. I (R5 = NHOH).

.apprx.70 Example preps. of intermediates and products are given.

Inhibition rates for some of the claimed compds. are reported for gelatinase A (MMP-2), gelatinase B (MMP-9) and collagenase (MMP-1).

IT 367517-49-5P, (2R)-2-[[2-(4-Methoxyphenylthio)benzothiazole-6-sulfonyl]amino]-3-[4-(3-phthalimidopropyl)oxyphenyl]propionic acid methyl ester



RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. of benzimidazole-, benzoxazole- and benzothiazolesulfonamide amino acid derivs. as selective matrix metalloproteinase inhibitors)

RN 367517-49-5 CA

CN D-Tyrosine, O-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-N-[[2-[(4-methoxyphenyl)thio]-6-benzothiazolyl]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 367517-49-5P, (2R)-2-[[2-(4-Methoxyphenylthio)benzothiazole-6-sulfonyl]amino]-3-[4-(3-phthalimidopropyl)oxyphenyl]propionic acid methyl ester 367517-50-8P, (2R)-2-[[2-(4-Methoxyphenylthio)benzothiazole-6-sulfonyl]amino]-3-[4-(3-phthalimidopropyl)oxyphenyl]propionic acid  
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (prepn. of benzimidazole-, benzoxazole- and benzothiazolesulfonamide amino acid derivs. as selective matrix metalloproteinase inhibitors)

REFERENCE COUNT: 5

REFERENCE(S):

- (1) Du Pont Pharm Co; WO 9941246 A 1999 CA
- (2) Monsanto Co; WO 9803166 A 1998 CA
- (3) Pfizer Prod Inc; WO 9952862 A 1999 CA
- (4) Warner Lambert Co; WO 9809934 A 1998 CA
- (5) Zeneca Ltd; WO 9807742 A 1998 CA

L11 ANSWER 2 OF 4 CA COPYRIGHT 2001 ACS

ACCESSION NUMBER: 134:71498 CA

TITLE: Preparation of heterocycllyl substituted benzenesulfonamides and pyridinesulfonamides for the modulation of PPAR.gamma. activity

INVENTOR(S): McGee, Lawrence R.; Houze, Jonathan B.; Rubenstein, Steven M.; Hagiwara, Atsushi; Furukawa, Noboru; Shinkai, Hisashi

PATENT ASSIGNEE(S): Tularik Inc., USA; Japan Tobacco Inc.

SOURCE: PCT Int. Appl., 232 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001000579	A1	20010104	WO 2000-US18178	20000628
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 1999-141672 P 19990630

OTHER SOURCE(S): MARPAT 134:71498

GI



AB The title compds. [I; Ar<sup>1</sup> = (un)substituted aryl; X = alkylene, O, alkyleneoxy, etc.; Y = alkylene, O, CO, etc.; R<sup>1</sup> = H, heteroalkyl, aryl, halo, etc.; R<sup>2</sup> = (un)substituted aryl; R<sup>3</sup> = halo, CN, NO<sub>2</sub>, alkoxy] which are modulators of PPAR. $\gamma$  activity and therefore are useful for the treatment of conditions such as type II **diabetes** and obesity, were prepd. E.g., a multi-step synthesis of the benzenesulfonamide II which showed IC<sub>50</sub> of < 1  $\mu$ M against PPAR. $\gamma$  binding, was given.


IT 315225-25-3P

RL: BAC (Biological activity or effector, except adverse); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of heterocyclyl substituted benzenesulfonamides and pyridinesulfonamides for the modulation of PPAR. $\gamma$  activity)

RN 315225-25-3 CA

CN Benzenesulfonamide, 2-chloro-N-[3,5-dichloro-4-[(6-cyano-2-benzothiazolyl)thio]phenyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



IT 315225-25-3P 315225-29-7P 315225-31-1P  
RL: BAC (Biological activity or effector, except adverse); RCT (Reactant);  
SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological  
study); PREP (Preparation); USES (Uses)  
(prepn. of heterocyclyl substituted benzenesulfonamides and  
pyridinesulfonamides for the modulation of PPAR.gamma. activity)

IT 315222-46-9P 315222-47-0P 315222-49-2P  
315222-51-6P 315222-53-8P 315222-55-0P  
315222-57-2P 315222-59-4P 315222-61-8P  
315222-63-0P 315222-65-2P 315222-67-4P  
315222-69-6P 315222-70-9P 315222-72-1P  
315222-74-3P 315222-76-5P 315222-77-6P  
315222-78-7P 315222-80-1P 315222-82-3P  
315222-83-4P 315222-84-5P 315222-86-7P  
315222-88-9P 315222-90-3P 315222-92-5P  
315222-94-7P 315222-96-9P 315222-98-1P  
315223-00-8P 315225-00-4P 315225-02-6P  
315225-04-8P 315225-05-9P 315225-06-0P  
315225-08-2P 315225-09-3P 315225-10-6P  
315225-11-7P 315225-12-8P 315225-13-9P  
315225-14-0P 315225-16-2P 315225-18-4P  
315225-19-5P 315225-21-9P 315225-23-1P  
315225-27-5P 315225-33-3P 315225-35-5P  
315225-37-7P 315225-39-9P 315225-41-3P  
315225-43-5P 315225-45-7P 315225-47-9P  
315225-49-1P 315225-51-5P 315225-91-3P  
315225-93-5P 315225-95-7P 315225-97-9P  
315225-99-1P 315226-01-8P 315226-03-0P  
315226-05-2P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic  
preparation); THU (Therapeutic use); BIOL (Biological study); PREP  
(Preparation); USES (Uses)  
(prepn. of heterocyclyl substituted benzenesulfonamides and  
pyridinesulfonamides for the modulation of PPAR.gamma. activity)

REFERENCE COUNT: 33

REFERENCE(S): (1) Baguley, B; CA  
(2) Baguley, B; EUR J CANCER CLIN ONCOL 1988, V24(2),  
P205 CA  
(3) Bayer Ag; EP 0261539 A 1988 CA  
(4) Bridges, A; WO 9906378 A 1999 CA  
(5) Burmistrov, K; CA  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 3 OF 4 CA COPYRIGHT 2001 ACS

ACCESSION NUMBER: 111:4058 CA

TITLE: Relationships between the chemical structures of  
**drugs** and their antimycobacterial activity  
against atypical strains. II. 6-Acylamido-2-  
alkylthiobenzothiazoles, quantitative  
structure-spectrum of activities analysis  
AUTHOR(S): Machacek, Milos; Kunes, J.; Sidoova, E.; Odlerova, Z.;  
Waisser, K.


CORPORATE SOURCE: Farm. Fak., Univ. Karlovy, Hradec Kralove, 50165,  
Czech.

SOURCE: Cesk. Farm. (1989), 38(1), 9-15  
CODEN: CKFRAY; ISSN: 0009-0530

DOCUMENT TYPE: Journal

LANGUAGE: Czech

GI



I


AB Forty-six 6-acylamido-2-alkylthiobenzothiazoles were tested in vitro for antimicrobial activity to Mycobacterium. The logarithms of the min. inhibitory concns. are shown. The relationships between chem. structure and activity were studied by the Free-Wilson method. The contributions of the substituents in positions 2 and 6 and the contribution of the common benzothiazole part to the activity are shown. Total antimycobacterial activity was increased by alkyl radicals branched in position 1' or 2', a cyclopentyl group bound to the S atom in position 2, and an o-chlorobenzamide group in position 6. 6-Benzamido-2-(sec-butyl)thiobenzothiazole (I) is a very effective **drug**.

IT 120912-32-5

RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (tuberculostatic activity of)

RN 120912-32-5 CA

CN Benzamide, N-[2-(phenylthio)-6-benzothiazolyl]- (9CI) (CA INDEX NAME)



NO

IT 120912-32-5 120912-33-6

RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (tuberculostatic activity of)

L11 ANSWER 4 OF 4 CA COPYRIGHT 2001 ACS

ACCESSION NUMBER: 108:94553 CA

TITLE: Preparation of benzimidazoles, benzoxazoles, and benzothiazoles as gastric acid secretion inhibitors

INVENTOR(S): Cox, David; Hall, David Edward; Ingall, Anthony Howard; Suschitzky, John Louis

PATENT ASSIGNEE(S): Fisons PLC, UK

SOURCE: Eur. Pat. Appl., 23 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 220053	A2	19870429	EP 1986-307962	19861015
EP 220053	A3	19880210		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
FI 8604138	A	19870417	FI 1986-4138	19861014
US 4851419	A	19890725	US 1986-918832	19861014

09/606,433

DK 8604933	A	19870417	DK 1986-4933	19861015
NO 8604110	A	19870421	NO 1986-4110	19861015
NO 167569	B	19910812		
NO 167569	C	19911120		
JP 62135462	A2	19870618	JP 1986-243304	19861015
ZA 8607827	A	19870729	ZA 1986-7827	19861015
AU 8664169	A1	19870430	AU 1986-64169	19861016
AU 599607	B2	19900726		
IL 80339	A1	19930610	IL 1986-80339	19861016

PRIORITY APPLN. INFO.:

GB 1985-25452	19851016
GB 1985-25454	19851016
GB 1986-21768	19860910

GI For diagram(s), see printed CA Issue.


AB The title heterocycles [I; R = Q; n = 1; y = 0, 1; adjacent pairs of R1-R8 = (CH2)x (x = 3-5), 6-membered carbocyclic or N-contg. heterocyclic ring; ring A represents a benzene or 5- or 6-membered, N- or S-contg. heterocyclic ring; L = bond or group contg. 1 or 2 C atoms; R1-R8 = H, halo, PhO, (fluoro)alkyl, alkanoyl, PhCO, NO2, (substituted) NH2, CO2H, ester or amide residue, (phenyl)alkoxy, R10S(O)p; p = 0-2; R10 = H, (alkyl)phenyl, (phenyl)alkyl; R9 = (substituted) NH2, cyclic amino; X = S, O, (substituted) NH], useful as cytoprotective agents in the treatment of **inflammatory** conditions and/or prevention or inhibition of gastric acid secretion (no data), were prepd. Methylation of (2-H2NC6H4S)2 with (MeO)2SO2 in H2O contg. NaHCO3, followed by redn. with LiAlH4 in THF, gave 2-Me2NC6H4SH which was condensed with 2-chlorobenzimidazole in DMF at 80.degree. for 1 h to give, after oxidn. with m-ClC6H4C(O)OOH, (phenylsulfonyl)benzimidazole II. Pellet, capsule and granule formulations contg. I are described.

IT 112903-43-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and oxidn. of)

RN 112903-43-2 CA

CN Benzothiazole, 2-[[2-(2-pyridinyl)phenyl]thio]- (9CI) (CA INDEX NAME)



IT 112903-43-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and oxidn. of)

IT 112951-73-2P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of, as cytoprotective agent, for treatment of ulcers and inflammation)

=> file uspatfull

=> s 13

L12 12 L3

=> d ibib abs fhitr hitrn 1-12

L12 ANSWER 1 OF 12 USPATFULL

09/606,433

ACCESSION NUMBER: 1999:159741 USPATFULL  
TITLE: Photothermographic material  
INVENTOR(S): Inagaki, Yoshio, Kanagawa, Japan  
Tsuzuki, Hirohiko, Kanagawa, Japan  
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Kanagawa, Japan (non-U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5998125		19991207
APPLICATION INFO.:	US 1997-949694		19971015 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1996-293332	19961015
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Chea, Thorl	
LEGAL REPRESENTATIVE:	Birch, Stewart, Kolasch & Birch, LLP	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1367	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A photothermographic material comprising at least one layer containing photosensitive silver halide grains on a support further contains a mono-, tri- or penta-methine cyanine dye having a thienyl or arylthio substituent. The material shows low fog, high sensitivity, and improved age stability.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 208125-68-2

(thermally developable silver halide photog. emulsion contg. cyanine sensitizer dye with low fog)

RN 208125-68-2 USPATFULL

CN Benzothiazolium, 3-butyl-2-[[3-[[3-butyl-5-(phenylthio)-2(3H)-benzothiazolylidene]methyl]-5,5-dimethyl-2-cyclohexen-1-ylidene]methyl]-5-(phenylthio)-, iodide (9CI) (CA INDEX NAME)



● I<sup>-</sup>

IT 208125-68-2 208125-69-3

(thermally developable silver halide photog. emulsion contg. cyanine sensitizer dye with low fog)

L12 ANSWER 2 OF 12 USPATFULL

ACCESSION NUMBER: 1999:106286 USPATFULL  
TITLE: Photothermographic material  
INVENTOR(S): Inagaki, Yoshio, Ashigara, Japan



PATENT ASSIGNEE(S): Oya, Toyohisa, Ashigara, Japan  
 Kobayashi, Katsumi, Ashigara, Japan  
 Tsuzuki, Hirohiko, Ashigara, Japan  
 Fuji Photo Film Co., Ltd., Kanagawa, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5948608		19990907
APPLICATION INFO.:	US 1997-840715		19970425 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1996-105788	19960425
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Chea, Thorl	
LEGAL REPRESENTATIVE:	Birch, Stewart, Kolasch & Birch, LLP	
NUMBER OF CLAIMS:	14	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1365	


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A photothermographic material comprising light-sensitive silver halide grains, with the photosensitive material further comprising a heptamethine cyanine dye containing at least one arylthio or thienyl group as substituent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 200401-13-4  
 (heat-developable photosensitive material contg. heptamethinecyanine dye)

RN 200401-13-4 USPATFULL  
 CN Benzothiazolium, 3-butyl-2-[[3-[3-[3-butyl-5-(phenylthio)-2(3H)-benzothiazolylidene]-1-propenyl]-5,5-dimethyl-2-cyclohexen-1-ylidene]methyl]-5-(phenylthio)-, iodide (9CI) (CA INDEX NAME)



● I<sup>-</sup>

IT 200401-13-4 200401-15-6  
 (heat-developable photosensitive material contg. heptamethinecyanine dye)

IT 199457-89-1P  
 (heat-developable photosensitive material contg. heptamethinecyanine dye)

L12 ANSWER 3 OF 12 USPATFULL

ACCESSION NUMBER: 1998:119159 USPATFULL

TITLE: Inhibitors of amyloid beta-protein production

INVENTOR(S): Heinz, Lawrence J., Pittsboro, IN, United States  
 Panetta, Jill A., Zionsville, IN, United States  
 Phillips, Michael L., Indianapolis, IN, United States  
 Reel, Jon K., Carmel, IN, United States  
 Shadle, John K., Fishers, IN, United States  
 Simon, Richard L., Greenwood, IN, United States  
 Whitesitt, Celia A., Greenwood, IN, United States  
 PATENT ASSIGNEE(S): Eli Lilly and Company, Indianapolis, IN, United States  
 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5814646		19980929
APPLICATION INFO.:	US 3981886		19950302 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Rotman, Alan L.		
ASSISTANT EXAMINER:	Mach, D. Margaret M.		
LEGAL REPRESENTATIVE:	Palmberg, Arleen, Boone, David E.		
NUMBER OF CLAIMS:	6		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1610		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of protecting a warm-blooded mammal from the progression of Alzheimer's disease, which comprises administering an effective amount of a compound of general formula. ##STR1## in which: R.sup.1 represents an optionally substituted aromatic or heteroaromatic group;

L.sup.1 and L.sup.2 each independently represents a bond or an unbranched (1-4C) alkylene group, which alkylene group may optionally bear a (1-4C) alkyl, phenyl or phenyl (1-2C) alkyl substituent;

one of Y.sup.1 and Y.sup.2 represents NR.sup.3 and the other represents O, S or NR.sup.3, in which R.sup.3 represent hydrogen, hydroxyl, (1-4C) alkoxy, (1-4C) alkyl or di (1-4C) alkylamino;

Z represents O or S; and

R.sup.2 represents (3-8C) cycloalkyl, heterocyclyl, and optionally substituted aromatic or heteroaromatic group, or together with L.sup.2, (1-10C) alkyl;

or a pharmaceutically acceptable salt thereof.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 190331-20-5P

(prepn. of (hetero)arylthiureas and analogs as amyloid .beta.-protein biosynthesis inhibitors)

RN 190331-20-5 USPATFULL

CN Thiourea, N-[4-(2-benzothiazolylthio)phenyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



IT 190331-20-5P 190331-21-6P

(prepn. of (hetero)arylthioureas and analogs as amyloid .beta.-protein biosynthesis inhibitors)

L12 ANSWER 4 OF 12 USPATFULL

ACCESSION NUMBER: 1998:95554 USPATFULL

TITLE: Antifungal agents, processes for the preparation thereof, and intermediates

INVENTOR(S): Naito, Toshihiko, Ibaraki Prefecture, Japan  
 Hata, Katsura, Ibaraki Prefecture, Japan  
 Kaku, Yumiko, Ibaraki Prefecture, Japan  
 Tsuruoka, Akihiko, Ibaraki Prefecture, Japan  
 Tsukada, Itaru, Ibaraki Prefecture, Japan  
 Yanagisawa, Manabu, Ibaraki Prefecture, Japan  
 Toyosawa, Toshio, Ibaraki Prefecture, Japan  
 Nara, Kazumasa, Ibaraki Prefecture, Japan

PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5792781		19980811
APPLICATION INFO.:	US 1996-710668		19960918 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-382158, filed on 1 Feb 1995, now patented, Pat. No. US 5648372		

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1994-33268	19940207
	JP 1994-174894	19940705
	JP 1994-208203	19940810
	JP 1994-306467	19941209

DOCUMENT TYPE: Utility  
 FILE SEGMENT: Granted  
 PRIMARY EXAMINER: McKane, Joseph  
 ASSISTANT EXAMINER: Lutz, Laura Cross  
 LEGAL REPRESENTATIVE: Wenderoth, Lind & Ponack, L.L.P.  
 NUMBER OF CLAIMS: 5  
 EXEMPLARY CLAIM: 1  
 LINE COUNT: 4259

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A compound represented by the general formula: ##STR1## wherein R.sup.1 and R.sup.2 denote a halogen atom or hydrogen atom; R.sup.3 means a hydrogen atom or lower alkyl group; l, r and m stand for 0 or 1; A is N or CH; W denotes an aromatic ring or a condensed ring thereof; X means another aromatic ring, an alkanediyl group, an alkenediyl group, or an alkynediyl group; Y stand for --S--, etc.; Z denotes a hydrogen atom, etc., or a salt thereof, and intermediates thereof or a salt thereof as well as processes for the preparation thereof, and pharmaceutical

composition suitable for use as an antifungal agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 170862-35-8P

(prepn. of azole antifungal agents)

RN 170862-35-8 USPATFULL

CN 2-Benzothiazoleethanol, .alpha.-(2,4-difluorophenyl)-6-[(4-fluorophenyl)sulfonyl]-.beta.-methyl-.alpha.-(1H-1,2,4-triazol-1-ylmethyl)-, (R\*,S\*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 170862-35-8P 170863-04-4P 170863-05-5P

170863-06-6P

(prepn. of azole antifungal agents)

L12 ANSWER 5 OF 12 USPATFULL

ACCESSION NUMBER: 1998:92050 USPATFULL

TITLE: Antifungal agents, processes for the preparation thereof, and intermediates

INVENTOR(S): Naito, Toshihiko, Ibaraki Prefecture, Japan  
Hata, Katsura, Ibaraki Prefecture, Japan  
Kaku, Yumiko, Ibaraki Prefecture, Japan  
Tsuruoka, Akihiko, Ibaraki Prefecture, Japan  
Tsukada, Itaru, Ibaraki Prefecture, Japan  
Yanagisawa, Manabu, Ibaraki Prefecture, Japan  
Toyosawa, Toshio, Ibaraki Prefecture, Japan  
Nara, Kazumasa, Ibaraki Prefecture, Japan

PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5789429		19980804
APPLICATION INFO.:	US 1997-810283		19970303 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-382158, filed on 1 Feb 1995, now patented, Pat. No. US 5648372		

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1994-33268	19940207
	JP 1994-174894	19940715
	JP 1994-208203	19940810
	JP 1994-306467	19941209

DOCUMENT TYPE: Utility  
FILE SEGMENT: Granted  
PRIMARY EXAMINER: Richter, Johann  
ASSISTANT EXAMINER: Cross Lutz, Laura R.

LEGAL REPRESENTATIVE: Wenderoth, Lind &amp; Ponack, L.L.P.

NUMBER OF CLAIMS: 4

EXEMPLARY CLAIM: 1

LINE COUNT: 4253

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A compound represented by the general formula: ##STR1## wherein R.sup.1 and R.sup.2 denote a halogen atom or hydrogen atom; R.sup.3 means a hydrogen atom or lower alkyl group; l, r and m stand for 0 or 1; A is N or CH; W denotes an aromatic ring or a condensed ring thereof; X means another aromatic ring, an alkanediyl group, an alkenediyl group, or an alkynediyl group; Y stand for --S--, etc.; Z denotes a hydrogen atom, etc., or a salt thereof, and intermediates thereof or a salt thereof as well as processes for the preparation thereof, and pharmaceutical composition suitable for use as an antifungal agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 170862-35-8P

(prepn. of azole antifungal agents)

RN 170862-35-8 USPATFULL

CN 2-Benzothiazoleethanol, .alpha.-(2,4-difluorophenyl)-6-[(4-fluorophenyl)sulfonyl]-.beta.-methyl-.alpha.-(1H-1,2,4-triazol-1-ylmethyl)-, (R\*,S\*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 170862-35-8P 170863-04-4P 170863-05-5P  
170863-06-6P

(prepn. of azole antifungal agents)

L12 ANSWER 6 OF 12 USPATFULL

ACCESSION NUMBER: 97:61703 USPATFULL

TITLE: Antifungal agents, and compositions

INVENTOR(S): Naito, Toshihiko, Ibaraki, Japan

Hata, Katsura, Ibaraki, Japan

Kaku, Yumiko, Ibaraki, Japan

Tsuruoka, Akihiko, Ibaraki, Japan

Tsukada, Itaru, Ibaraki, Japan

Yanagisawa, Manabu, Ibaraki, Japan

Toyosawa, Toshio, Ibaraki, Japan

Nara, Kazumasa, Ibaraki, Japan

PATENT ASSIGNEE(S): Eisai Co., Ltd., Tokyo, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5648372		19970715
APPLICATION INFO.:	US 1995-382158		19950201 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1994-33268	19940207
	JP 1994-174894	19940705
	JP 1994-208203	19940810
	JP 1994-306467	19941209
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Richter, Johann	
ASSISTANT EXAMINER:	Cross, Laura R.	
LEGAL REPRESENTATIVE:	Wenderoth, Lind & Ponack	
NUMBER OF CLAIMS:	4	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3976	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A compound represented by the general formula: ##STR1## wherein R.sup.1 and R.sup.2 denote a halogen atom or hydrogen atom; R.sup.3 means a hydrogen atom or lower alkyl group; l, r and m stand for 0 or 1; A is N or CH; W denotes an aromatic ring or a condensed ring thereof; X means another aromatic ring, an alkanediyl group, an alkenediyl group, or an alkynediyl group; Y stand for --S--, etc.; Z denotes a hydrogen atom, etc., or a salt thereof, and intermediates thereof or a salt thereof as well as processes for the preparation thereof, and pharmaceutical composition suitable for use as an antifungal agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 170862-35-8P

(prepn. of azole antifungal agents)

RN 170862-35-8 USPATFULL

CN 2-Benzothiazoleethanol, .alpha.-(2,4-difluorophenyl)-6-[(4-fluorophenyl)sulfonyl]-.beta.-methyl-.alpha.-(1H-1,2,4-triazol-1-ylmethyl)-, (R\*,S\*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 170862-35-8P 170863-04-4P 170863-05-5P  
170863-06-6P

(prepn. of azole antifungal agents)

L12 ANSWER 7 OF 12 USPATFULL

ACCESSION NUMBER: 97:36197 USPATFULL

TITLE: Chemical compounds as inhibitors of amyloid beta protein production

INVENTOR(S): Reel, Jon K., Carmel, IN, United States  
Simon, Richard L., Greenwood, IN, United States  
Whitesitt, Celia A., Greenwood, IN, United States

PATENT ASSIGNEE(S): Eli Lilly and Company, Indianapolis, IN, United States

(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5624937		19970429
APPLICATION INFO.:	US 1995-397466		19950302 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Ivy, C. Warren		
ASSISTANT EXAMINER:	Huang, Evelyn		
LEGAL REPRESENTATIVE:	Palmberg, Arleen, Hay, Martin A., Boone, David E.		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
LINE COUNT:	946		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A compound of the formula I in which ##STR1## Z is O or S; R.sup.11 is a halogen atom;

R.sup.12 is a halogen atom or a trifluoromethyl group; and

X is S, SO, SO.sub.2, O or NH;

R.sup.4 is naphthyl, quinolinyl, benzimidazolyl, pyridyl, pyradazinyl, benzoxazolyl or benzothiazolyl, unsubstituted or substituted by one or two substituents selected from a halogen atom, (1-4C)alkyl, (1-4C)alkoxy, nitro, (1-4C)alkoxycarbonyl, halo(1-4C)alkyl, and phenyl;

or a pharmaceutically acceptable salt thereof.

The compounds are useful as inhibitors of amyloid beta-protein production.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 190331-20-5P

(prepn. of N-[4-(heterocyclylthio)phenyl]-N'-phenylureas and -thioureas as inhibitors of amyloid beta-protein prodn.)

RN 190331-20-5 USPATFULL

CN Thiourea, N-[4-(2-benzothiazolylthio)phenyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



IT 190331-20-5P 190331-21-6P

(prepn. of N-[4-(heterocyclylthio)phenyl]-N'-phenylureas and -thioureas as inhibitors of amyloid beta-protein prodn.)

L12 ANSWER 8 OF 12 USPATFULL

ACCESSION NUMBER: 90:11337 USPATFULL

TITLE: 2-Pyridinyl-phenyl-sulphonyl-and-phenyl-thio-benzimidazoles having antiinflammatory or gastric acid

secretion inhibition activity  
 INVENTOR(S): Cox, David, Loughborough, England  
 Dowlatsahi, Hossein A., Loughborough, England  
 Hall, David E., Wymeswold, England  
 Ingall, Anthony H., Loughborough, England  
 Suschitzky, John L., Loughborough, England  
 PATENT ASSIGNEE(S): Fisons plc, Ipswich, England (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4900751		19900213
APPLICATION INFO.:	US 1987-100584		19870924 (7)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1986-918832, filed on 14 Oct 1986, now patented, Pat. No. US 4851419, issued on 25 Jul 1989		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1986-23299	19860927
	GB 1986-23301	19860927
	GB 1987-5017	19870304
	GB 1987-19644	19870820

DOCUMENT TYPE: Utility  
 FILE SEGMENT: Granted  
 PRIMARY EXAMINER: Fan, Jane T.  
 LEGAL REPRESENTATIVE: Marshall, O'Toole, Gerstein, Murray & Bicknell  
 NUMBER OF CLAIMS: 9  
 EXEMPLARY CLAIM: 1  
 LINE COUNT: 2269

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of formula I, ##STR1## in which A is a 5 or 6 membered, fully unsaturated, carbocyclic or heterocyclic ring,

B is a 5 or 6 membered, fully unsaturated, nitrogen containing heterocyclic ring,

X is NR.sub.19, O or S,

R.sub.19 is hydrogen or alkyl optionally substituted by --OCOR,

n is 0 or 1,

R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9 and R.sub.10 have various significances,

R.sub.1 and R.sub.2, are hydrogen or alkyl or together with the ring carbon atoms to which they are attached, form a benzene or pyridine ring, which ring carries substituents R.sub.15, R.sub.16, R.sub.17 and R.sub.18,

R.sub.15, R.sub.16, R.sub.17 and R.sub.18, have various

significances, with certain provisos are described.

Processes for making the compounds and pharmaceutical formulations containing them, e.g. for the treatment of conditions including excess gastric acid secretion, are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 112903-43-2P




09/606,433

(prepn. and oxidn. of)

RN 112903-43-2 USPATFULL

CN Benzothiazole, 2-[[2-(2-pyridinyl)phenyl]thio]- (9CI) (CA INDEX NAME)



IT 112903-43-2P

(prepn. and oxidn. of)

IT 112951-73-2P

(prepn. of, as cytoprotective agent, for treatment of ulcers and inflammation)

L12 ANSWER 9 OF 12 USPATFULL

ACCESSION NUMBER: 89:60886 USPATFULL

TITLE: Certain 2-pyridinyl-phenylsulfinyl-benzoxazoles, the corresponding benzothiazoles or benzimidazoles having anti-inflammatory or gastric acid secretion inhibition activity

INVENTOR(S): Cox, David, Loughborough, England  
Hall, David E., Loughborough, England  
Ingall, Anthony H., Loughborough, England  
Suschitzky, John L., Loughborough, England

PATENT ASSIGNEE(S): Fisons plc, Ipswich, England (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4851419		19890725
APPLICATION INFO.:	US 1986-918832		19861014 (6)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1985-25452	19851016
	GB 1985-25454	19851016
	GB 1986-21768	19860910

DOCUMENT TYPE:

Utility

FILE SEGMENT:

Granted

PRIMARY EXAMINER:

Rotman, Alan L.

LEGAL REPRESENTATIVE:

Marshall, O'Toole, Gerstein, Murray & Bicknell

NUMBER OF CLAIMS:

6

EXEMPLARY CLAIM:

1,6

LINE COUNT:

1055

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There are described compounds of formula I, ##STR1## in which A is a benzene or heterocyclic ring, y is 0 or 1,

L is a group containing 1 or 2 carbon atoms, or is a single bond,

R.sub.9 and R.sub.10 have a variety of significances, e.g.

R.sub.10 may form part of a double bond with L, or

the group --NR.sub.9 R.sub.10 forms a ring carrying substituents R.sub.1

and R.sub.8, or

when L is a single bond --NR.sub.10 and R.sub.8 may form a ring carrying substituents R.sub.16 to R.sub.25, or

the group --LNR.sub.9 R.sub.10 forms a heterocyclic ring carrying substituents R.sub.26 to R.sub.33,

R.sub.1 to R.sub.8 and R.sub.16 to R.sub.33 have a variety of significances

n is 0, 1 or 2,

x is 3, 4 or 5,

X is S, O or NR.sub.15,

R.sub.15 is hydrogen, --COR, --COOR or alkyl optionally substituted by --OCOR,

and certain provisos.

Processes for making the compounds and pharmaceutical formulations containing them, e.g. for the treatment of conditions involving excess gastric acid secretion, are also described.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 112903-43-2P

(prepn. and oxidn. of)

RN 112903-43-2 USPATFULL

CN Benzothiazole, 2-[[2-(2-pyridinyl)phenyl]thio]- (9CI) (CA INDEX NAME)



IT 112903-43-2P

(prepn. and oxidn. of)

IT 112951-73-2P

(prepn. of, as cytoprotective agent, for treatment of ulcers and inflammation)

L12 ANSWER 10 OF 12 USPATFULL

ACCESSION NUMBER: 86:59331 USPATFULL

TITLE: Silver halide color photographic light-sensitive material

INVENTOR(S): Ichijima, Seiji, Kanagawa, Japan  
Usui, Hideo, Kanagawa, Japan

PATENT ASSIGNEE(S): Deguchi, Naoyasu, Kanagawa, Japan  
Fuji Photo Film Co., Ltd., Kanagawa, Japan (non-U.S. corporation)

NUMBER KIND DATE

-----

09/606,433

PATENT INFORMATION: US 4618571 19861021  
APPLICATION INFO.: US 1985-705473 19850225 (6)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1984-33059	19840223
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Downey, Mary F.	
LEGAL REPRESENTATIVE:	Sughrue, Mion, Zinn, Macpeak & Seas	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1839	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A silver halide color photographic light-sensitive material comprising a support having thereon at least one silver halide emulsion layer, the color photographic light-sensitive material containing a coupler which releases a compound after the coupling reaction with the oxidation product of a developing agent, the released compound being capable of releasing further a photographically useful group by an oxidation-reduction reaction with the oxidation product of another developing agent. The compound used in the present invention is chemically stable and can release a photographically useful group under control; therefore the silver halide color photographic light-sensitive material containing the compound has good stability during storage and high sensitivity and provides a color image having good image qualities such as sharpness, graininess, color reproducibility, etc.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 101208-40-6

(photog. development inhibitor-releasing coupler)

RN 101208-40-6 USPATFULL

CN 2-Naphthalenecarboxamide, 4-[3-(2-benzothiazolylthio)-4-hydroxyphenoxy]-N-hexadecyl-1-hydroxy- (9CI) (CA INDEX NAME)



IT 101208-40-6

(photog. development inhibitor-releasing coupler)

L12 ANSWER 11 OF 12 USPATFULL

ACCESSION NUMBER: 81:37017 USPATFULL

TITLE: Magenta-masked color azopyrazolinone couplers

INVENTOR(S): Whitear, Brian R. D., Hutton, England

PATENT ASSIGNEE(S): Ciba-Geigy AG, Basel, Switzerland (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4277398		19810707
APPLICATION INFO.:	US 1979-64660		19790808 (6)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1977-843628, filed on 19 Oct 1977, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1976-47423	19761115
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Doll, John	
LEGAL REPRESENTATIVE:	Sprung, Felfe, Horn, Lynch & Kramer	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIM:	1	
LINE COUNT:	377	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Orange colored magenta color couplers of the general formula ##STR1## are provided, in which R is optionally substituted alkyl, aralkyl, aryl or a heterocyclic group, X is optionally substituted aryl, Y is optionally substituted acyl-amino, aroyl amino or aryl amino and Z represents further optional substituents of the phenyl ring. Preferably Y also contains a ballasting group, which is a long claim alkyl group having 10 to 24 carbon atoms in the chain.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 67178-62-5P

(manuf. of, as masked magenta coupler for photog.)

RN 67178-62-5 USPATFULL

CN Butanamide, N-[4-chloro-3-[[4-[[4-[(5,6-dimethoxy-2-benzothiazolyl)thio]phenyl]azo]-4,5-dihydro-5-oxo-1-(2,4,6-trichlorophenyl)-1H-pyrazol-3-yl]amino]phenyl]-2-[4-(1,1-dimethylpropyl)phenoxy]-(9CI) (CA INDEX NAME)



IT 67178-62-5P 67202-97-5P

(manuf. of, as masked magenta coupler for photog.)

L12 ANSWER 12 OF 12 USPATFULL

ACCESSION NUMBER: 75:52592 USPATFULL

TITLE: Fogged, direct positive silver halide emulsion sensitized with a nitrophenyl mercapto heterocyclic compound

INVENTOR(S): Shiba, Keisuke, Kanagawa, Japan  
Hinata, Masanao, Kanagawa, Japan

PATENT ASSIGNEE(S): Ohi, Reiichi, Kanagawa, Japan  
 Shishido, Tadao, Kanagawa, Japan  
 Fuji Photo Film Co., Ltd., Kanagawa, Japan (non-U.S.  
 corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 3910795		19751007
APPLICATION INFO.:	US 1973-426146		19731219 (5)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1972-127575	19721219
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Louie, Jr., Won H.	
LEGAL REPRESENTATIVE:	Sughrue, Rothwell, Mion, Zinn & Macpeak	
NUMBER OF CLAIMS:	26	
EXEMPLARY CLAIM:	1	
LINE COUNT:	534	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A silver halide photographic emulsion for direct positives, containing at least one compound represented by the general formula (I), ##SPC1##

in which Z represents a group of non-metallic atoms necessary for forming a heterocyclic ring and n represents an integer of from 1 to 3.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 54188-92-0

(photog. sensitizer, for direct-pos. emulsions)


RN 54188-92-0 USPATFULL

CN Hexanediamide, N,N'-bis[2-[(2,4-dinitrophenyl)thio]-6-benzothiazolyl]-  
 (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



IT 54188-92-0

(photog. sensitizer, for direct-pos. emulsions)

09/606,433

=> d his

(FILE 'HOME' ENTERED AT 14:28:09 ON 20 NOV 2001)

FILE 'REGISTRY' ENTERED AT 14:28:19 ON 20 NOV 2001

L1 STRUCTURE UPLOADED

L2 30 S L1 SAM

L3 447 S L1 FULL

FILE 'CA' ENTERED AT 14:29:12 ON 20 NOV 2001

L4 52 S L3

L5 750639 S PHARM? OR DRUG?

L6 2 S L4 AND L5

L7 297393 S DIABE? OR HYPERCHOLEST? OR LIPOPRO? OR TRIGLYCER? OR INFLAMM?

L8 2 S L7 AND L4

L9 2 S L7 AND L8

L10 297393 S L7 OR L8

L11 4 S L8 OR L6

FILE 'USPATFULL' ENTERED AT 14:31:20 ON 20 NOV 2001

L12 12 S L3

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

STN INTERNATIONAL LOGOFF AT 14:32:37 ON 20 NOV 2001